Dosing & TLS prophylaxis
(tumour lysis syndrome)
VENCLYXTO®▼in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1
Starting treatment for AML with VENCLYXTO,
a BCL-2 inhibitor, in combination with AZACITIDINE1
VENCLYXTO®▼ (VENETOCLAX) FOR NEWLY-DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY1
Please refer to SmPC before prescribing
Prescribing information can be accessed by the Prescribing Information button on the left
UK-VNCAML-220096 | November 2022.
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]
